-
NYU Dataset
Sequencing Data for a Delta-Omicron Recombinant in an Immunosuppressed Transplant Recipient Treated with Monoclonal Antibody Sotrovimab
- Authors
- Ralf DuerrHao ZhouTakuya TadaDacia Dimartino18 more author(s)...
- Description
A Delta-Omicron recombinant of the SARS-CoV-2 virus was sequenced and isolated from an immunosuppressed and unvaccinated male kidney transplant patient who received Sotrovimab for treatment of COVID-19. Further clinical details and medical history of the patient are described in the associated publication. Sotrovimab is a therapeutic monoclonal antibody (mAb) used to treat infections by the BA.1 Omicron...
- Subject
-
COVID-19GenomicsInfectious Disease
- Timeframe
- 2022
- Access Rights
- Free to AllApplication Required
-
NYU Dataset
Structural Characterization of Monoclonal Antibodies Targeting Ser404 Region of Phosphorylated Tau Protein
- Authors
- Jessica E. ChukwuErin E. CongdonEinar M. SigurdssonXiang-Peng Kong
- Description
Tau is one of the major microtubule-associated proteins in neurons. Its main role is to stabilize microtubules, supporting cytoskeletal organization, and axonal transport. Tau may undergo pathological modifications and become hyperphosphorylated. This causes the protein to accumulate into toxic assemblies that collectively lead to neurodegeneration. In Alzheimer's disease, tau proteins change shape...
- Subject
-
NeuroscienceProteomics
- Access Rights
- Free to All
-
NYU Dataset
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19
- Alternate Title(s)
- Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE, ACTIV4-ACUTE, ACTIV4A
- Authors
- Matthew D. NealJudith S. HochmanScott SolomonMikhail Kosiborod1 more author(s)...
- Description
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV4A) is a randomized, open label, adaptive platform trial that compares the effectiveness of several antithrombotic strategies for the prevention of adverse outcomes in COVID-19 positive inpatients. Investigators assessed outcomes such as the number of days that a patient is alive and free of organ support through the first 21...
- Subject
-
COVID-19Infectious Disease
- Access Rights
- Fee RequiredApplication RequiredAuthor Approval Required
